Ampelopsin exerts its anti-cancer ability through the regulation of growth factor receptor (VEGFR2 and PDGFRβ) and TRAIL/TRAIL-R pathways [48]; moreover, its anti-inflammatory ability is exerted through the modulation of the toll-like receptor 4 (TLR4) pathway [49] or binding to the ryanodine receptor [50]. Here, PDGFRB is linked to cancer.